Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) insider Jared Gollob sold 46,137 shares of Kymera Therapeutics stock in a transaction on Friday, February 9th. The shares were sold at an average price of $35.50, for a total transaction of $1,637,863.50. Following the completion of the sale, the insider now directly owns 74,709 shares of the company’s stock, valued at approximately $2,652,169.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Kymera Therapeutics Stock Performance
Shares of KYMR opened at $37.21 on Friday. The company has a 50-day simple moving average of $27.69 and a 200-day simple moving average of $20.97. The firm has a market capitalization of $2.06 billion, a P/E ratio of -12.97 and a beta of 2.23. Kymera Therapeutics, Inc. has a 52 week low of $9.60 and a 52 week high of $37.26.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on the stock. HC Wainwright cut their target price on shares of Kymera Therapeutics from $85.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, November 3rd. Morgan Stanley cut their target price on shares of Kymera Therapeutics from $37.00 to $24.00 and set an “equal weight” rating for the company in a research report on Monday, November 13th. Wells Fargo & Company lowered shares of Kymera Therapeutics from an “overweight” rating to an “equal weight” rating and set a $26.00 target price for the company. in a research report on Tuesday, December 19th. Piper Sandler cut their target price on shares of Kymera Therapeutics from $58.00 to $38.00 and set an “overweight” rating for the company in a research report on Friday, November 3rd. Finally, Leerink Partnrs reissued a “market perform” rating on shares of Kymera Therapeutics in a research report on Monday, October 16th. Five investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.88.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD raised its position in shares of Kymera Therapeutics by 34.1% during the second quarter. Price T Rowe Associates Inc. MD now owns 5,224,686 shares of the company’s stock valued at $102,874,000 after buying an additional 1,329,481 shares during the last quarter. Vanguard Group Inc. increased its stake in Kymera Therapeutics by 4.9% in the third quarter. Vanguard Group Inc. now owns 3,925,213 shares of the company’s stock valued at $54,560,000 after acquiring an additional 182,125 shares during the period. State Street Corp increased its stake in Kymera Therapeutics by 67.8% in the second quarter. State Street Corp now owns 3,514,438 shares of the company’s stock valued at $69,199,000 after acquiring an additional 1,419,877 shares during the period. BlackRock Inc. increased its stake in Kymera Therapeutics by 0.6% in the first quarter. BlackRock Inc. now owns 3,419,084 shares of the company’s stock valued at $144,698,000 after acquiring an additional 21,544 shares during the period. Finally, Wellington Management Group LLP increased its stake in Kymera Therapeutics by 19.7% in the first quarter. Wellington Management Group LLP now owns 3,225,749 shares of the company’s stock valued at $136,514,000 after acquiring an additional 530,935 shares during the period.
Kymera Therapeutics Company Profile
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
- Five stocks we like better than Kymera Therapeutics
- How to Use Stock Screeners to Find Stocks
- Cloudflare results spark analysts reset: 25% upside ahead
- 3 Healthcare Dividend Stocks to Buy
- Beyond Nvidia: The hidden stars with 200% earnings growth
- Learn Technical Analysis Skills to Master the Stock Market
- 3 large caps with RSIs that scream ‘oversold’
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.